{"id":391139,"date":"2016-05-12T00:00:00","date_gmt":"2016-05-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biolatr010-2016-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-2-us-2016\/"},"modified":"2026-03-31T09:02:12","modified_gmt":"2026-03-31T09:02:12","slug":"biolatr010-2016-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-2-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biolatr010-2016-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-2-us-2016\/","title":{"rendered":"Biosimilars | Emerging Biosimilars | Oncology | Zarxio Wave 2 | US | 2016"},"content":{"rendered":"<p><em>LaunchTrends: Zarxio (Wave 2)<\/em> is the second in a series of syndicated reports designed to track physician perception and uptake of Sandoz\u2019s Zarxio (filgrastim-sndz), a biosimilar of Amgen\u2019s Neupogen and the first biosimilar to launch in the United States.<\/p>\n<p>The study surveys medical oncologists and hematology-oncologists in the United States and assesses the formulary coverage and restrictions associated with Zarxio and other products in the granulocyte colony-stimulating factor (G-CSF) class. These reports evaluate physicians\u2019 awareness and perception of Zarxio, uptake of the biosimilar over time, Zarxio&#8217;s effect on other G-CSFs, and promotional activity related to Zarxio and other G-CSF products.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>Zarxio launched in the United States in September 2015. <strong>Are U.S. oncologists aware of the biosimilar and of how it was tested during clinical development?<\/strong><\/li>\n<li>Biosimilars are intended to share the clinical profile of the reference brand; therefore, a clinical benefit over the brand is not expected to be associated with their use. <strong>Why have physicians chosen to prescribe Zarxio or an alternative G-CSF?<\/strong><\/li>\n<li>Pharmacists in the United States are not permitted to substitute the reference brand Neupogen for Zarxio, because Zarxio was approved as a biosimilar, not an interchangeable biological product; thus, physicians must directly prescribe Zarxio for their patients to receive it. <strong>What promotional messages are sales representatives using for Zarxio and other G-CSF brands to influence physician prescribing?<\/strong><\/li>\n<li>Zarxio is the first biosimilar to launch in the United States. As such, the industry has no prior experience of how managed care organizations will incorporate Zarxio into formularies. <strong>Which formulary tier and what restrictions, if any, are being applied to Zarxio, and how does it compare with other G-CSFs?<\/strong><\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-391139","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391139\/revisions"}],"predecessor-version":[{"id":394262,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391139\/revisions\/394262"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}